<DOC>
	<DOCNO>NCT00873223</DOCNO>
	<brief_summary>This trial conduct United States . The aim clinical trial investigate whether chronic liraglutide administration affect mode action ( pharmacokinetics ) insulin detemir</brief_summary>
	<brief_title>Examination Effects Liraglutide Mode Action Insulin Detemir</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Diagnosed type 2 diabetes BMI le 45.0 kg/m2 Insulin naive Currently treat Oral AntiDiabetic drug ( OADs ) metformin HbA1c 7.0 9.5 % currently treat metformin HbA1c 7.0 10.0 % Any clinically significant disease type 2 diabetes Currently use daily insulin Thiazolidinione use injectable diabetes medication within last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>